Full metadata record

DC Field Value Language
dc.contributor.authorCho, Jung-Kyo-
dc.contributor.authorChun, ChanJu-
dc.contributor.authorKuh, Hyo-Jeong-
dc.contributor.authorSong, Soo-Chang-
dc.date.accessioned2024-01-20T14:05:11Z-
dc.date.available2024-01-20T14:05:11Z-
dc.date.created2021-09-05-
dc.date.issued2012-08-
dc.identifier.issn0939-6411-
dc.identifier.urihttps://pubs.kist.re.kr/handle/201004/129023-
dc.description.abstractThe objective of this study is to develop an effective polymer therapeutics involving camptothecin (CPT) with enhanced efficacy and lessened systemic side-toxicity for cancer treatment. Polymer-CPT conjugates (PCCs), which consisted of CPT-20-glycinate and poly(organophosphazene) bearing carboxylic acid, were synthesized, characterized for physicochemical properties, in vitro degradation and CPT release behaviors from the PCC, and evaluated their anticancer activity. The aqueous solutions of all these PCCs showed a thermo-responsive sol-gel transition behavior for injectable application near room temperature. The CPT incorporated into the hydrogel was proven to be stable in vitro over 15 days. The in vitro cytotoxicity of the PCC was verified to be effective against four kinds of human cancer cell lines. The in vivo anticancer activity study with HT-29 colon cancer cell xenografted mice showed that the intratumorally injected PCC hydrogel inhibited the tumor growth more effectively relative to CPT alone (-29% vs. 130% in tumor size). Crown Copyright (C) 2012 Published by Elsevier B.V. All rights reserved.-
dc.languageEnglish-
dc.publisherELSEVIER SCIENCE BV-
dc.subjectPOLYMER THERAPEUTICS-
dc.subjectSPACER GROUPS-
dc.subjectCAMPTOTHECIN-
dc.subjectCANCER-
dc.subjectPOLYPHOSPHAZENES-
dc.subjectEFFICACY-
dc.subjectDELIVERY-
dc.titleInjectable poly(organophosphazene)-camptothecin conjugate hydrogels: Synthesis, characterization, and antitumor activities-
dc.typeArticle-
dc.identifier.doi10.1016/j.ejpb.2012.04.008-
dc.description.journalClass1-
dc.identifier.bibliographicCitationEUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, v.81, no.3, pp.582 - 590-
dc.citation.titleEUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS-
dc.citation.volume81-
dc.citation.number3-
dc.citation.startPage582-
dc.citation.endPage590-
dc.description.journalRegisteredClassscie-
dc.description.journalRegisteredClassscopus-
dc.identifier.wosid000307040900015-
dc.identifier.scopusid2-s2.0-84863774652-
dc.relation.journalWebOfScienceCategoryPharmacology & Pharmacy-
dc.relation.journalResearchAreaPharmacology & Pharmacy-
dc.type.docTypeArticle-
dc.subject.keywordPlusPOLYMER THERAPEUTICS-
dc.subject.keywordPlusSPACER GROUPS-
dc.subject.keywordPlusCAMPTOTHECIN-
dc.subject.keywordPlusCANCER-
dc.subject.keywordPlusPOLYPHOSPHAZENES-
dc.subject.keywordPlusEFFICACY-
dc.subject.keywordPlusDELIVERY-
dc.subject.keywordAuthorAntitumor activity-
dc.subject.keywordAuthorPoly(organophosphazene)-
dc.subject.keywordAuthorThermosensitive hydrogel-
dc.subject.keywordAuthorPolymer-drug conjugate-
dc.subject.keywordAuthorStability of camptothecin-
Appears in Collections:
KIST Article > 2012
Files in This Item:
There are no files associated with this item.
Export
RIS (EndNote)
XLS (Excel)
XML

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

BROWSE